Emulate Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022 

Leading Organ-Chip technology company ranked #4 in the biotech category

Boston, MA – March 8, 2022 –  Emulate, Inc., a leading provider of next-generation in vitro models, today announced that it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2022.

This year’s list honors businesses that are making the biggest impact on their industries and culture as a whole—ultimately, thriving in today’s ever-changing world. These companies are creating the future today with some of the most inspiring accomplishments of the 21st century.

“As a first-time recipient of this award, we are honored to be among this distinguished group of innovators and recognized for our Organ-Chip technology which disrupts pharmaceutical preclinical workflows that have not been able to keep up with today’s global health needs,” said Emulate CEO Jim Corbett. “This accomplishment reflects the commitment of our team to setting a new standard for the drug discovery and development process that reduces the need for animal testing and leads to safer and more effective drugs.” 

Over the past year, Emulate has achieved several significant milestones starting with the completion of the single largest Organ-Chip study to date, which demonstrated that the use of the human Liver-Chip could improve patient safety and better predict drug toxicity than other methods for modeling drug-induced liver injury. 

The Emulate Brain-Chip, which became commercially available in 2021, is the most comprehensive in vitro model of the human neurovascular unit, including the blood-brain barrier, for preclinical research. It was recently sent to the International Space Station U.S. National Laboratory to study the effects of microgravity on human brain physiology as part of the Tissue-Chips in Space initiative. This year, the Company also launched its Colon Intestine-Chip, which can be used by researchers investigating inflammatory intestinal diseases, to recapitulate specific human colon cell functionality, gain a greater understanding of mechanisms of inflammation, and investigate potential drug targets. 

Emulate also strengthened its commitment to leveraging Organ-Chip technology as an alternative to animal testing, by supporting legislation and endorsing both the U.S. Food and Drug Administration’s (FDA) Modernization Act of 2021 and the Humane Research and Testing Act of 2021, which call for alternatives to animal testing, citing scientific inadequacies and ethical concerns associated with animal models. 

Fast Company’s editors and writers sought out the most groundbreaking businesses across the globe and industries. They also judged nominations received through their application process. 

The World’s Most Innovative Companies is Fast Company’s signature franchise and one of its most highly anticipated editorial efforts of the year. It provides both a snapshot and a road map for the future of innovation across the most dynamic sectors of the economy. 

“The world’s most innovative companies play an essential role in addressing the most pressing issues facing society, whether they’re fighting climate change by spurring decarbonization efforts, ameliorating the strain on supply chains, or helping us reconnect with one another over shared passions,” said Fast Company Deputy Editor David Lidsky. 

For the second year in a row, to coincide with the issue launch, Fast Company will host its Most Innovative Companies Summit on April 26–27. The virtual, multiday summit celebrates the Most Innovative Companies in business, and provides an early look at major business trends and an inside look at what it takes to innovate in 2022. Fast Company’s Most Innovative Companies issue (March/April 2022) is available online here, as well as in-app form via iTunes, and on newsstands beginning March 15. The hashtag is #FCMostInnovative. 

For more information on Emulate, please visit emulatebio.com

About Emulate, Inc.
Emulate is igniting a new era in human health with industry-leading Organ-on-a-Chip technology. The Human Emulation System provides a window into the inner workings of human biology and disease — offering researchers an innovative technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Pioneered at the Wyss Institute for Biologically Inspired Engineering at Harvard University and backed by Northpond Ventures, Founders Fund, and Perceptive Advisors, Organ-on-a-Chip technology is assisting researchers across academia, pharma, and government industries through its predictive power and ability to recreate true-to-life human biology. To learn more, visit emulatebio.com or follow us on LinkedIn and Twitter

About Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at fastcompany.com.

Media Contact: 

Michael Sullivan
Emulate, Inc.
+1 503-799-7420